FDA Roundtable: Strengthening the Supply Chain for Blood Manufacturing

This is a public roundtable convened by the FDA's Center for Biologics Evaluation and Research (CBER), Office of Blood Research and Review, on strengthening supply-chain resilience for the collection and manufacturing of Whole Blood, blood components and Source Plasma. It runs as a free virtual meeting on 29 September 2026, with registration required and public-comment requests taken in advance.

Blood and plasma are temperature-controlled products whose availability depends on a fragile chain of collection supplies, equipment and logistics, and this roundtable is where FDA, industry and blood establishments discuss the resilience of that chain directly with the US regulator. For blood cold-chain professionals it is a rare open window on FDA's supply-chain thinking.

FDA/CBER staff, blood establishments and blood-center operators, plasma-industry and manufacturing stakeholders, equipment and supplies vendors, and public commenters. Being virtual and free, attendance is broad; the content is regulatory and supply-chain rather than clinical.